Microbiota-centered interventions to boost immune checkpoint blockade therapies.

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, improving patient survival by enhancing antitumor immunity.
• However, significant challenges persist, including therapeutic resistance and immune-related adverse events.
• Growing evidence links gut microbial dysbiosis to reduced ICB efficacy, while a diverse gut microbiome and specific beneficial bacteria are associated with better responses.

Purpose of the Study:

• To review current strategies for manipulating the gut microbiome to enhance cancer therapy efficacy.
• To examine novel diagnostic tools for detecting gut dysbiosis.
• To highlight existing challenges and future directions in microbiome-targeted cancer immunotherapy.

Main Methods:

• Literature review of studies investigating the gut microbiome's role in cancer immunotherapy.
• Analysis of emerging therapeutic approaches targeting the gut microbiota.
• Evaluation of diagnostic technologies for microbial dysbiosis.

Main Results:

• Gut microbial composition significantly influences response to immune checkpoint blockade.
• Specific bacterial taxa and overall gut microbial diversity correlate with improved treatment outcomes.
• Targeting the gut microbiome presents a promising avenue for overcoming therapeutic resistance.

Conclusions:

• Modulating the gut microbiota holds significant potential to improve the efficacy of cancer immunotherapies.
• Development of precise diagnostic tools is crucial for identifying patients who may benefit from microbiome interventions.
• Further research is needed to address challenges in microbiome manipulation for optimized cancer treatment.